Evaluating Depemokimab Early Therapy in COPD
Phase 3
1,196
about 4.2 years
40–75
1 site in FL
What this study is about
Researchers are testing whether early treatment with depemokimab, added to standard care, improves outcomes for people with moderate to severe COPD and type 2 inflammation. The trial will last about 1500 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Depemokimab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Secondary: Change from Baseline in Evaluating Respiratory Symptoms (E-RS): COPD Total Score at Week 52, Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
Respiratory